Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.

MLA

Kadia, Tapan M., et al. “Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.” NEJM Evidence, vol. 3, no. 6, June 2024, p. EVIDoa2300362. EBSCOhost, https://doi.org/10.1056/EVIDoa2300362.

APA

Kadia, T. M., Huang, M., Pemmaraju, N., Abbas, H. A., Ly, C., Masarova, L., Yilmaz, M., Lyu, M.-A., Zeng, K., Sadeghi, T., Cook, R., DiNardo, C. D., Daver, N., Issa, G. C., Jabbour, E., Borthakur, G., Jain, N., Garcia-Manero, G., Parmar, S., … Verstovsek, S. (2024). Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evidence, 3(6), EVIDoa2300362. https://doi.org/10.1056/EVIDoa2300362

Chicago

Kadia, Tapan M, Meixian Huang, Naveen Pemmaraju, Hussein A Abbas, Christopher Ly, Lucia Masarova, Musa Yilmaz, et al. 2024. “Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.” NEJM Evidence 3 (6): EVIDoa2300362. doi:10.1056/EVIDoa2300362.